Two New Promising Treatments

Exciting developments in sarcoma research have brought forth two promising treatments that hold immense potential for transforming the landscape of sarcoma care. SaRC-Q is thrilled to share the latest breakthroughs: Nirogacestat and CART Therapy.

1. Nirogacestat: Opening New Avenues in Sarcoma Treatment
Nirogacestat, a novel investigational drug, has shown promise in inhibiting the Notch signaling pathway, a key player in the growth of certain types of sarcoma. Early clinical trials indicate encouraging results, suggesting that Nirogacestat could be a game-changer in the pursuit of more effective and targeted sarcoma therapies. SaRC-Q is closely monitoring and participating in ongoing research to further evaluate the potential of Nirogacestat in the fight against sarcoma.

2. CART Therapy: Revolutionizing Immunotherapy for Sarcoma
Chimeric Antigen Receptor T-cell (CART) Therapy is an innovative form of immunotherapy that harnesses the power of the patient’s immune system to target and destroy sarcoma cells. This groundbreaking approach involves genetically modifying a patient’s T cells to express receptors that recognize and attack cancer cells. SaRC-Q is actively involved in exploring the efficacy and safety of CART Therapy in sarcoma patients through clinical trials. And, we are happy to share that the first patient was enrolled through McGill to Calgary’s CART Clinical trial. SaRC-Q remains dedicated to staying at the forefront of sarcoma research, relentlessly pursuing advancements that can make a meaningful difference in the lives of patients.

We will continue to provide updates on these promising treatments as we work towards a future where sarcoma is no longer a life-altering threat. Stay tuned for more updates, and let’s journey together towards a brighter future in sarcoma care!

First patient enrolled in new Clinical Trial

Thanks to the efforts and dedication of our co-founder Dr. Ramy Saleh, McGill enrolled the first patient into the Calgary’s Cart T cell trial for advanced alveolar soft-part sarcoma.

SaRC-Q Co-founder Dr. Ramy Saleh Leads Milestone in Sarcoma Research
In a significant milestone for sarcoma research, SaRC-Q co-founder Dr. Ramy Saleh has played a pivotal role in enrolling the first patient into the Calgary’s CART T-cell trial for advanced alveolar soft-part sarcoma (ASPS).

A Step Forward in Advanced Alveolar Soft-Part Sarcoma Treatment
Dr. Ramy Saleh’s dedication and tireless efforts have led to McGill’s enrollment in the cutting-edge CART T-cell trial, offering hope to those facing advanced alveolar soft-part sarcoma. CART T-cell therapy, a revolutionary immunotherapy approach, involves harnessing the patient’s immune system to target and combat cancer cells.

A Testament to SaRC-Q’s Commitment
This achievement underscores SaRC-Q’s commitment to pushing the boundaries of sarcoma research. Dr. Saleh’s leadership exemplifies the collaborative spirit and unwavering dedication of our team in advancing innovative treatments for rare and challenging forms of sarcoma.

A Brighter Future in Sarcoma Care
SaRC-Q congratulates Dr. Ramy Saleh and the entire team at McGill for this groundbreaking accomplishment. Enrolling the first patient into the Calgary’s CART T-cell trial is a significant step forward in our collective mission to transform the future of sarcoma care.

Stay tuned for further updates as we continue to strive for advancements that make a meaningful impact on the lives of sarcoma patients.

Registry Active & Running

We are pleased to announce that SaRC-Q is now active! We look forward to seeing the database’s impact on Sarcoma cancer-care.

This marks a significant milestone in our relentless pursuit of advancing sarcoma research and transforming cancer care. The launch of our comprehensive database signifies a new era in the fight against Sarcoma.

Empowering Sarcoma Cancer-Care Through Data
SaRC-Q’s active status means that our dedicated team is now harnessing the power of data to make a meaningful impact on Sarcoma cancer-care. The robust database will serve as a valuable resource, providing insights into patient demographics, tumor characteristics, treatment outcomes, and more. This wealth of information is pivotal in shaping the future of sarcoma care in Quebec and beyond.

A Platform for Innovation and Collaboration
SaRC-Q is more than a database; it’s a platform for innovation and collaboration. By bringing together medical professionals, researchers, and patients, we aim to foster an environment where cutting-edge treatments and transformative breakthroughs become a reality. Together, we envision a future where sarcoma is not only treatable but conquerable.

Join Us on This Journey
We invite you to explore the possibilities that SaRC-Q brings to the forefront of sarcoma research. Whether you are a healthcare professional, researcher, or someone passionate about making a difference, your involvement is crucial. Together, let’s push the boundaries of knowledge and redefine the landscape of sarcoma cancer-care.

SaRC-Q is active, and the journey has just begun. Stay tuned for updates, breakthroughs, and stories of resilience as we work towards a brighter future in sarcoma care.

Thank you for being part of this transformative journey.

All Clinical Trials in One Place

A new platform that aims to bring all clinical trials that include Sarcoma patients under one roof was launched.

Centralizing Sarcoma Clinical Trials for Enhanced Research
The launch of the SaRC-Q Registry signifies a major leap forward in sarcoma research. This unique platform consolidates information from various clinical trials, providing a centralized and accessible hub for researchers, healthcare professionals, and patients. By bringing these trials under one roof, we aim to accelerate the pace of research, promote collaboration, and enhance the overall understanding of sarcoma.

Empowering Patients and Advancing Research
For patients, the SaRC-Q Registry offers a user-friendly interface to explore available clinical trials, empowering them with valuable information about potential treatment options. For researchers and healthcare professionals, it provides a comprehensive view of ongoing trials, facilitating collaboration and the exchange of critical insights. Together, we are creating a dynamic space where the sarcoma community can come together for a common purpose — to advance research and improve patient outcomes.

Join Us in the Sarcoma Research Revolution
We invite you to navigate the SaRC-Q Registry, explore the array of clinical trials, and join us in this revolutionizing journey. Your participation and engagement are vital as we strive to bring sarcoma research to new heights.

Stay tuned for more updates, insights, and collaborative opportunities. Together, let’s make a difference in the world of sarcoma research.

Eight Hospitals Joined Forces

In a collaborative effort to improve services for Sarcoma Patients in Quebec, 8 hospitals have joined forces for the first time.

A Unified Front for Sarcoma Care
This groundbreaking collaboration represents a significant stride towards improving the quality of care for individuals facing Sarcoma in Quebec. The joint efforts of these eight hospitals aim to establish a seamless network, ensuring that Sarcoma patients receive comprehensive and unified support throughout their journey. To know more about the participating sites and physicians, visit our About Us Page.

Enhancing Services Through Collective Expertise
Pooling together a wealth of expertise, resources, and specialized care, the collaborative initiative is designed to enhance and streamline services. From diagnosis to treatment and beyond, this unified front is dedicated to providing Sarcoma patients with the highest standard of care, combining medical excellence with a compassionate approach.

Transforming the Landscape of Sarcoma Care
This collaborative venture signifies not only a commitment to individual patient well-being but also a collective dedication to transforming the overall landscape of Sarcoma care. By fostering an environment of collaboration, knowledge-sharing, and innovation, these hospitals are poised to make a lasting impact on the lives of Sarcoma patients and their families.

Join Us in Celebrating this Milestone
We invite you to join us in celebrating this remarkable milestone for Sarcoma care in Quebec. Together, we can build a future where every Sarcoma patient receives unparalleled support and where collaboration paves the way for groundbreaking advancements in treatment and care.

Stay connected for updates, stories of resilience, and the continued journey towards enhancing Sarcoma services.


In a major step forward for Sarcoma cancer care, HMR will join forces with MUHC for Sarcoma trials.

Forging a Path for Sarcoma Research
This pivotal collaboration marks a significant step forward in the quest for enhanced Sarcoma treatments. By uniting the expertise and resources of HMR and MUHC, this partnership aims to push the boundaries of research, fostering an environment where innovative trials and treatments can flourish.

A Unified Approach to Advancing Care
The collaboration between HMR and MUHC represents a unified approach to advancing Sarcoma care. By combining the strengths of two renowned institutions, the focus is not only on individual patient outcomes but also on contributing to the broader landscape of Sarcoma research and treatment.

Empowering Patients Through Collaboration
This collaborative effort is not just about institutions; it’s about the individuals affected by Sarcoma. By working together, HMR and MUHC are dedicated to empowering patients with access to cutting-edge trials and personalized care, bringing hope to those facing this challenging disease.

Celebrate the Beginning of a New Era
Join us in celebrating this significant milestone in Sarcoma research and care. Together, let’s honor the spirit of collaboration that is shaping a new era for Sarcoma patients in Quebec and beyond.

Stay tuned for updates, breakthroughs, and stories of progress as we continue to forge ahead in the fight against Sarcoma.